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Available online 21 July 2008This paper, like others before it, concludes that carotid
stenting (CAS) is less cost-effective than carotid endarter-
ectomy (CEA). As a surgeon, this appeals to my own
prejudices, but will it stand up to the more critical gaze
of enthusiastic stenters?
The authors have developed a cost-effectiveness model
based on procedural costs for both CEA and CAS in their own
institutions in the Netherlands and clinical outcomes from
the ECST,1 a Cochrane Review of randomised controlled
trials2 (RCTs) and the Global Carotid Artery Stent Registry
(Wholey3). The crucial questions are 1) Do the costs in
this paper reflect wider practice? 2) Are the clinical out-
comes used by the authors reasonable?
The issue of costs is relatively straightforward. By providing
a breakdown of how these were calculated (Table 1), we can
all compare and contrast with our own figures. The paper
overestimates CEA costs for my own unit as we discharge
patientswithin 48 hours of operation, don’t use TCD and in the
UK an interventional radiologist costs roughly the same as
a surgeon, rather than half as much (though I like the Dutch
valuation). We don’t run a stenting programme but those that
do will no doubt find similar faults with the CAS costs.
However, it does seem clear that the kit used for CAS is
considerably more expensive than that used for CEA. So, if the
benefit of a shorter hospital stay is lost, do the clinical
outcomes of CAS justify this additional expense?* Corresponding author. Tel.: 01603 287552.
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doi:10.1016/j.ejvs.2008.06.014This rather polarised debate boils down to which out-
comes you choose to believe. For those you don’t like you
can always invoke the ‘‘learning curve’’, ‘‘evolving tech-
niques’’ or ‘‘my own results’’.
By basing their model on results from the ECST (an old
trial), Cochrane database (disputed trials) and the Wholey
registry (not a trial) the authors will be subjected to familiar
criticisms. They have, however, used the best available
evidence. By using different scenarios and sources of data
they have endeavoured to do this in an even-handed way. The
crucial figure (fig. 3) in this paper, comparing costs and QALYs,
finds the Cochrane RCTs showing a clear advantage for CEA,
with the Wholey database winning the argument for CAS over
ECST (in what could be argued was a rather uneven contest).
Both sides will draw comfort from this, but how were such
conflicting results obtained? The explanation is found in
Figure 1, where the confidence intervals for major and minor
stroke rates following CAS in the Cochrane trials and the
Wholey registry do not even come close to overlapping. The
learning curve or selective reporting? You decide.
What this paper contributes is a useful model into which
individual centres can put their own figures. Differing local
costs and outcomes will make the case for one technique or
the other. It is incumbent on manufacturers of stenting
equipment to also look long and hard at these figures. In
any normal marketplace if an expensive technology has no
proven advantage over a cheaper alternative, producers
would be forced to cut prices or go out of business. But the
healthcare economy is not a normal marketplace and
clinicans are rarely swayed by economic arguments. If wed by Elsevier Ltd. All rights reserved.
266 M.P. Armonwere, this paper suggests that we should no longer be
debating this subject.
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